Clearmind Medicine (NASDAQ: CMND) links July 31, 2025 interim results to U.S. shelf

Rhea-AI Filing Summary

Clearmind Medicine Inc. submitted a Form 6-K to inform investors that, on September 11, 2025, it filed in Canada its unaudited condensed interim consolidated financial statements and Management’s Discussion and Analysis for the three and nine months ended July 31, 2025. These documents were filed with the Canadian Securities Administration and the securities commissions in Ontario, British Columbia and Alberta.

The Form 6-K also states that this report is incorporated by reference into Clearmind’s existing U.S. registration statements on Form F-3 and Form S-8, meaning those offerings now formally include the latest Canadian interim financial statements and MD&A.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of September 2025

Commission file number: 001-41557

Clearmind Medicine Inc.

(Translation of registrant’s name into English)

101 – 1220 West 6th Avenue

Vancouver, British Columbia
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

CONTENTS

On September 11, 2025, Clearmind Medicine Inc. filed in Canada its unaudited condensed interim consolidated financial statements and Management’s Discussion and Analysis for the three and nine months ended July 31, 2025, with the Canadian Securities Administration and each of the Ontario Securities Commission, British Columbia Securities Commission and Alberta Securities Commission.

This Report on Form 6-K is incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File No. 333-275991, 333-270859, 333-273293) and Form S-8 (File No. 333-283695), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

EXHIBIT INDEX

Exhibit No.
99.1		Condensed Interim Consolidated Financial Statements for the three and nine months ended July 31, 2025.
99.2		Management’s Discussion and Analysis for the for the three and nine months ended July 31, 2025.
101.INS		Inline XBRL Instance Document.
101.SCH		Inline XBRL Taxonomy Extension Schema Document.
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Clearmind Medicine Inc.
Date: September 11, 2025	By:	/s/ Adi Zuloff-Shani
		Name:	Adi Zuloff-Shani
		Title:	Chief Executive Officer

3

FAQ

What did Clearmind Medicine Inc. (CMND) file in this Form 6-K?

Clearmind Medicine Inc. filed a Form 6-K to notify investors that it has submitted its unaudited condensed interim consolidated financial statements and Management’s Discussion and Analysis for the three and nine months ended July 31, 2025, with Canadian securities regulators.

Which periods do Clearmind Medicine’s (CMND) new financial statements cover?

The newly filed Canadian financial statements and MD&A for Clearmind Medicine cover the three and nine months ended July 31, 2025.

With which regulators did Clearmind Medicine (CMND) file its interim financials and MD&A?

Clearmind Medicine filed its interim financial statements and MD&A with the Canadian Securities Administration and the Ontario, British Columbia, and Alberta securities commissions.

How does this Form 6-K affect Clearmind Medicine’s (CMND) U.S. registration statements?

The Form 6-K states that this report is incorporated by reference into Clearmind’s U.S. registration statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and Form S-8 (File No. 333-283695). This means those registration statements now formally include the latest Canadian interim financials and MD&A.

Does this Clearmind Medicine (CMND) Form 6-K include detailed financial results?

This Form 6-K itself summarizes that unaudited interim financial statements and MD&A for the three and nine months ended July 31, 2025 have been filed and incorporated by reference; the detailed results are contained in the attached Canadian financial statement and MD&A exhibits.

Who signed Clearmind Medicine’s (CMND) September 2025 Form 6-K?

The Form 6-K was signed on behalf of Clearmind Medicine Inc. by Adi Zuloff-Shani, its Chief Executive Officer, dated September 11, 2025.